PD-1 blockade, a novel immunotherapy strategy, has gained widespread usage in treating diverse cancers, with several PD-1 inhibitor drugs approved by the Food and Drug Administration (FDA) for advanced gastric cancer (AGC) and other malignancies [4–6]. Here, PDCD1 is linked to cancer.